CALGARY, April 4, 2016 /PRNewswire/ - Resverlogix Corp. (the "Corporation") (TSX:RVX) is pleased to announce that Mrs. Norma K. Biln, Chief Executive Officer of Augurex, and Mr. Shawn Lu, Chief Financial Officer of Hepalink USA Inc. have been appointed to Resverlogix's Board of Directors.
"We are pleased to welcome these two experienced life science business leaders to Resverlogix's Board of Directors," stated Mr. Donald McCaffrey, President and Chief Executive Officer. "The addition to our Board with the appointments of Ms. Biln and Mr. Lu will ensure that Resverlogix will continue to benefit from a diversity of knowledge. The combined experience of their respective careers will be a tremendous asset to the company," further commented Mr. McCaffrey.
On the subject of their appointments, Ms. Biln stated, "It is a very exciting time to be joining Resverlogix's Board of Directors during the commencement of their phase 3 clinical trial in an indication with such a high unmet medical need. The cutting edge R&D and positive strategic energy throughout the organization is some of the best I have ever seen." Mr. Lu commented, "It is a great pleasure to join the Board and further foster the long-term partnership between Hepalink and Resverlogix. I look forward to sharing expertise amongst our respective companies."
Ms. Biln is the Chief Executive Officer and Co-Founder of Augurex. She has 22 years of experience in the pharmaceutical and biotech industries, commencing her career in clinical research with Pfizer Pharmaceuticals and held several positions in sales management, marketing and market access with Pfizer, Amgen and Abbott Laboratories where she won several regional and national level awards for top performance. Ms. Biln later joined Stressgen Biotechnologies as Director of Corporate Market Development and Director of Sales and Marketing for Stressgen Bioreagents. Before her role of CEO at Augurex, she worked in a senior consulting capacity with Aspreva Pharmaceuticals on Business Development, Commercial and Communications initiatives. Ms. Biln holds a Bachelor of Science and Master of Business Administration and is Chair of the Board of Directors of BioTalent Canada.
Mr. Lu is the Chief Financial Officer of Hepalink USA Inc. Mr. Lu has extensive experience in the areas of corporate finance, capital markets and investment financing spanning over 24 years. Prior positions include: Area Manager for BMO Bank of Montreal; TD Bank Residential Mortgage Manager; TD Bank Senior Financial Advisor; Chief Financial Officer and Vice President of Corporate Finance, Shenzhen Hepalink Biopharmaceutical Co.; Vice President of Investment and Corporate Finance, Shenzhen FuTianXin Investment Co.; General Manager of Corporate Finance Department and Manager of Investment & Finance Department, China Merchant Shekou Port Co. Ltd. Mr. Lu holds the following designations: Canadian Investment Manager (CIM) and a Certified Accountant and Certified Corporate Economist in China. He has Master of Finance Management and a Master of Corporate Economics and Business Administration.
In addition to the new Board member appointments, Dr. Peter Johann, Resverlogix's current chairman, has decided to step down from the Board of Directors. Dr. Johann has been a very valuable member of the Board since 2009 and he plans to personally remain an active supporter of Resverlogix with his continued efforts to introduce the company's world leading epigenetics program to his extensive international contacts in the pharmaceutical industry. The Board and management team wish Peter the best in his next venture heading the development of a global medical device program. The newly set Board will have Dr. Eldon Smith act as its Lead Director and Mr. Donald McCaffrey will act as its Chairman of the Board.
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL). Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog and via Twitter @Resverlogix_RVX https://twitter.com/resverlogix_rvx.
Donald J. McCaffrey
President and Chief Executive Officer
Director of Investor Relations & Corporate Communications
SOURCE Resverlogix Corp.